Multivariant coronavirus vaccine jabs are all-purpose vaccine jabs which work against more than one, or different variants of a pathogen, or in this case, the several variants of the SARS-COV-2 virus.

The first results of an early trial of a multivariant COVID-19 vaccine booster, launched in Manchester in September 2021, has shown it is driving a comprehensive immune response. US-based ...

A phase one trial of a multivariant COVID-19 Vaccine has been launched by US pharmaceutical company Gritstone in collaboration with The University of Manchester and Manchester University NHS ...

The initial phase one clinical data shows the vaccine has strong levels of neutralising antibodies, similar to approved mRNA vaccines, but at up to a 10-fold lower dose in the first 10 individuals.

London: A COVID-19 vaccine booster aimed at tackling multiple coronavirus variants shows promise in inducing a comprehensive immune response, early data suggests. The initial phase one clinical ...

Multivariant Covid-19 vaccine booster shows promise, early trial data suggests (Danny Lawson/PA) Tue, 04 Jan, 2022 - 12:16 Nina Massey, PA Science Correspondent ...

A phase one trial of a multivariant COVID-19 vaccine booster drug has got underway among participants aged over 60 in the UK. The trial, involving GRT-R910, has been launched by US pharmaceutical ...

Multivariant Covid-19 vaccine booster shows promise, early trial data suggests According to the data the vaccine was generally safe and well-tolerated. Nina Massey Tuesday 04 January 2022 12:00 GMT ...

Biotech Clover raises $230M as COVID-19 vaccine nears phase 3, multivariant prospect gets going By Nick Paul Taylor Feb 23, 2021 8:35am COVID-19 vaccines venture capital (VC) Clover Biopharmaceuticals ...